NEW YORK (GenomeWeb) – Novogene said this week that it has inked an agreement to offer Rockville, Maryland-based Full Genomes' whole-genome sequencing-based ancestry test in China.

Novogene, which is headquartered in Beijing, will run the $895 test, GenomeGuide, on its Illumina HiSeq X Ten. Customers will get back the raw data BAM file, variant summary reports from SnpEff and VEP that are compatible with third-party tools, autosomal and X-chromosomal variant identification VCF files, and mitochondrial and Y chromosome reports.

GenomeGuide is sold as a research-use-only test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.

Oct
24
Sponsored by
OmniSeq

This webinar will discuss the advantages of a multiple-biomarker-based approach for immune profiling that provides clinicians with a rational means to consider approved immunotherapies or assign patients to immunotherapy clinical trials.

Nov
02
Sponsored by
Qiagen

This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Nov
09
Sponsored by
NuGEN

This webinar will discuss the role of a newly discovered, brain-enriched form of non-CpG DNA methylation in neural development and disease.

Dec
05
Sponsored by
Agilent Technologies

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.